Clinical Trial ResultsPromising early data from ADI-001 in mantle cell lymphoma patients, with an 80% complete response rate observed.
Financial HealthAdicet's strong cash position, with approximately $271 million in cash and equivalents, provides a solid financial foundation and a cash runway into the second half of 2026.
Regulatory AdvancementsAdicet has received FDA Fast Track Designation for ADI-001 in the treatment of B-cell non-Hodgkin’s lymphoma, accelerating the development process.